Also known as: Forxiga, FORXIGA
Dapagliflozin is an oral SGLT2 inhibitor marketed as Farxiga/Forxiga for type 2 diabetes and also used in heart failure and chronic kidney disease populations. It lowers blood glucose by increasing urinary glucose excretion through renal SGLT2 inhibition. It is prescription-only in major markets.
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
AstraZeneca won a Federal Court injunction blocking Pharmacor from selling generic dapagliflozin products in Australia until a full patent trial. The patent expires October 22, 2027.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
The Federal Court of Australia granted AstraZeneca an interlocutory injunction on 16 February 2026 preventing Pharmacor from launching generic dapagliflozin products pending infringement proceedings, marking the second such injunction in three months.
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07729592 |
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome |
NOT_YET_RECRUITING | PHASE2 |
| NCT07684326 |
"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial" |
RECRUITING | PHASE2/PHASE3 |
| NCT07662109 |
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus |
RECRUITING | PHASE3 |
| NCT07662044 |
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus |
RECRUITING | PHASE3 |
| NCT07624305 |
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07491042 |
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. |
RECRUITING | NA |
| NCT07351643 |
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF |
NOT_YET_RECRUITING | PHASE4 |
| NCT07342764 |
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial |
NOT_YET_RECRUITING | PHASE4 |
| NCT07239570 |
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease |
RECRUITING | PHASE4 |
| NCT07239011 |
Dapagliflozin in Depression |
RECRUITING | PHASE1/PHASE2 |
